The futures have cooled off over the last hour or so thanks to inflation comments out of the ECB and not-so-jolly news from Target. So it looks like we won’t be making those higher highs today — or at least not early in the session.
On Today’s Calendar:
- nothing
More Calendars: U.S. Earnings | Conf. Calls | Surprises | IPO | Economic
Potential swing trades:
See one of the recent ‘Chart Reading‘ posts for some potential swing candidates.
Potential day trades:
(From Briefing.com)
Gapping Down
In reaction to weak earnings/guidance/same store sales: ZUMZ -8.0%, GIII -7.8%, FDO -7.3%, TGT -6.0%, CMTL -5.1%, JCP -4.0%, TOL -1.5%… Gold stocks seeing weakness as gold prices move lower; Feb gold is -$8.90 to $794.90: GFI -3.1%, DROOY -2.5%, GOLD -2.1%, AU -1.5%, AUY -1.0%… Other news: BCRX -9.0% (to discontinue Phase IIb trial of IV forodesine HCI), SRP -3.1% (announces a 12 mln share common stock offering), ACGY -2.8% (still checking), RTP -2.1% and BHP -2.3% (Baosteel says no plan to bid for RTP – Reuters), VMSI -1.5% (receives notice of intention to seek election of directors from Roche), MT -1.4% (to acquire assets of OFZ), AGN -1.1% (Botox maker Allergan faces challenge from MRX who has applied for FDA approval of competitor drug – WSJ), GENZ -1.1% (seeks to damp merger talk – WSJ),… Analyst downgrades: CHA -5.2% (initiated with Sell at Merrill), DRIV -3.8% (downgraded to Hold at Deutsche Securities), CTSH -2.6% (initiated with Market Perform at Friedman Billings), GS -1.5% (downgraded to Neutral at Merrill), WFC -1.3% (downgraded to Sell at Merrill).
Gapping Up
In reaction to strong earnings/guidance/same store sales: ENPT +39.9%, ALOY +38.2%, PLCE +5.4% (also restated financial statements to reflect additional stock-based compensation expense), PTMK +5.0%, JOSB +4.9%, MEI +4.4%, BONT +3.7%, BIDZ +3.3%, FNSR +3.1%, CASY +2.6%, CHINA +2.6%, GEF +2.5%, CAG +2.1% (also initiated with Outperform at Bear Sterns), DDMX +2.0%, CACH +1.9%, CWST +1.9%… Other news: HOKU +34.2% (announces progress on financing polysilicon plant, tgt raised to $15 at Broadpoint), NFI +25.0% (discloses waiver agreement with Wachovia), PTIE +15.8% (Remoxy meets primary endpoint in pivotal Phase III study), DRRX +13.7% (announces primary endpoint achieved in Phase II Remoxy Trial), THRX +7.2% (announces positive top-line results in Phase 3 Telavancin hospital-acquired pneumonia program), CPSL +7.0% (continued momentum following yesterday’s strength), CBAK +5.7% (continued momentum), RBS +4.7% (plans $2.53 bln write-down on its ABN subprime exposure), SEED +4.4% (continued momentum following yesterday’s 20% surge after the co made positive comments at a conference), CFC +4.1% (Cramer makes positive comments on MadMoney; Bush expected to unveil interest rate freeze on some mortgages), MTU +3.6% (gives notice in 6-k concerning issuance of “Non-dilutive” preferred securities), GME +3.5% (will replace DJ in the S&P 500), BEAV +3.5% (will replace GME in the S&P MidCap 400) MBI +2.8% (seeing moderate bounce after yesterday’s 20% sell-off following Moody’s comments), RMBS +2.8% (SEC notifies Rambus of termination of informal investigation), IMB +2.6% (CEO responds question from co’s blog posting, says will suffer loss in Q4 and received shareholder suggestion for buyback), HCBK +2.5% (Cramer makes positive comments on MadMoney), FCX +1.8% (Cramer makes positive comments on MadMoney), FRT +1.4% (Cramer makes positive comments on MadMoney), X +1.2% (prices $500 mln of senior unsecured notes), LAYN +1.0% (acquires Water and Wastewater Treatment Technologies with SolmeteX; accretive in FY09), FNM +1.0% ($7 bln preferred stock deal oversubscribed, according to source – DJ)… Analyst upgrades: PDLI +3.8% (upgraded to Equal-Weight at Lehman), HRP +1.3% (upgraded to Neutral at Merrill), PRFT +1.3% (initiated with Buy at Brean Murray).
Disclaimer & How I use this list
